Report Sections

See All Reports

  • HP:0001268: Mental deterioration
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001268: Mental deterioration

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (37)


    Name (Synonyms) Correlation
    drug1195 Dexamethasone 2 MG/ML Wiki 0.26
    drug1209 Diagnostic test Covid-19 Wiki 0.26
    drug299 Anthocyanins Wiki 0.26
    Name (Synonyms) Correlation
    drug503 Bacillus Calmette-Guerin (BCG) Wiki 0.26
    drug3911 Technology based social interactions Wiki 0.26
    drug3694 Stakeholder of TIP-OA Program Wiki 0.26
    drug957 Cognitive Stimulation Wiki 0.26
    drug2588 No research related technology based social interactions Wiki 0.26
    drug1932 Information leaflet Wiki 0.26
    drug2895 Physical Activity Wiki 0.26
    drug4269 WALC-R Wiki 0.26
    drug2367 Methylprednisolone Injection Wiki 0.26
    drug1644 Goal Management Training (GMT) Wiki 0.26
    drug471 BIIB107 Wiki 0.26
    drug2529 Neurocognitive assessment Wiki 0.26
    drug1190 Detection of anti-COVID-19 antibody level Wiki 0.26
    drug1071 Cooking Training Wiki 0.26
    drug1200 Dexmethylphenidate Wiki 0.26
    drug3896 Table Setting Training Wiki 0.26
    drug1203 Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta Wiki 0.26
    drug1211 Diagnostic test for detection of SARS-CoV-2 Wiki 0.26
    drug4265 Volunteer of TIP-OA Program Wiki 0.26
    drug779 COVID-19 swap test PCR Wiki 0.26
    drug1212 Dialectical Behavioral Therapy (DBT) Skills Wiki 0.26
    drug3934 Telephone interview Wiki 0.26
    drug483 BMS program Wiki 0.26
    drug3927 Telehealth phone calls Wiki 0.26
    drug1201 DiaNose Wiki 0.26
    drug1205 Diagnostic Test: serology test for COVID-19 Wiki 0.26
    drug1210 Diagnostic test for SARS-Cov2 for patients and health staff Wiki 0.26
    drug1921 Independent Living Program for Affordable Housing. Wiki 0.26
    drug1192 Device used to record voice for screening Wiki 0.26
    drug2443 Multi-tasking Training Wiki 0.26
    drug4066 Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit Wiki 0.18
    drug1193 Dexamethasone Wiki 0.17
    drug2365 Methylprednisolone Wiki 0.07
    drug2916 Placebo Wiki 0.02

    Correlated MeSH Terms (14)


    Name (Synonyms) Correlation
    D060825 Cognitive Dysfunction NIH 1.00
    D003072 Cognition Disorders NIH 0.37
    D003704 Dementia NIH 0.27
    Name (Synonyms) Correlation
    D008569 Memory Disorders NIH 0.26
    D004827 Epilepsy NIH 0.26
    D019965 Neurocognitive Disorders NIH 0.18
    D000544 Alzheimer Disease NIH 0.18
    D012640 Seizures NIH 0.15
    D009422 Nervous System Diseases NIH 0.12
    D003324 Coronary Artery Disease NIH 0.09
    D020521 Stroke NIH 0.06
    D040921 Stress Disorders, Traumatic NIH 0.05
    D007249 Inflammation NIH 0.04
    D013313 Stress Disorders, Post-Traumatic NIH 0.04

    Correlated HPO Terms (6)


    Name (Synonyms) Correlation
    HP:0000726 Dementia HPO 0.27
    HP:0002354 Memory impairment HPO 0.26
    HP:0002511 Alzheimer disease HPO 0.18
    Name (Synonyms) Correlation
    HP:0001250 Seizure HPO 0.13
    HP:0001677 Coronary artery atherosclerosis HPO 0.09
    HP:0001297 Stroke HPO 0.06

    Clinical Trials

    Navigate: Correlations   HPO

    There are 15 clinical trials


    1 Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment

    The aging US population threatens to overwhelm our healthcare infrastructure, especially since the rate of Alzheimer's disease (AD) alone is expected to triple in the coming decades. Memory cause functional impairment, reduced quality of life, increased caregiver burnout, and eventual institutionalization. The diagnosis of mild cognitive impairment (MCI) identifies those with memory deficits but who remain relatively independent in everyday life. MCI provides a window for interventions that target memory functioning. The proposed study focuses specifically on a groundbreaking combination of mnemonic rehabilitation and non-invasive brain stimulation. The main idea is that brain stimulation can enhance functioning in the specific brain regions/networks, thereby increasing the patients' ability to benefit from different types of memory rehabilitation. This will be a randomized, double-blind study (active vs. fake brain stimulation), that provides multiple treatment session. Outcome will be examined using both laboratory-based and real-world memory testing as well as brain imaging. This first-of-its-kind study has the potential to meaningfully translate more "basic" science findings into neuroanatomically targeted and functionally meaningful treatments for our aging population.

    NCT02155946
    Conditions
    1. Mild Cognitive Impairment
    2. Alzheimer's Disease
    Interventions
    1. Device: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
    2. Device: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
    MeSH:Alzheimer Disease Cognitive Dysfunction
    HPO:Alzheimer disease Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: Changes in task related and resting state BOLD activation.

    Measure: Functional MRI

    Time: 3 months

    Description: Performance measured using percent correct

    Measure: Face-name memory test performance

    Time: change from baseline

    Description: Performance measured using deviation from target position

    Measure: Object Location Association memory test performance

    Time: change from baseline

    Description: Changes in task related and resting state BOLD activation.

    Measure: fMRI

    Time: change from baseline to 3 months

    Description: Performance measured using percent correct

    Measure: Face-name memory test performance

    Time: change from baseline to 3 months

    Description: Performance measured using deviation from target position

    Measure: Object Location Association memory test performance

    Time: change from baseline to 3 months

    Secondary Outcomes

    Description: Performance on prose (medical instructions) and spatial (navigation) memory tasks

    Measure: Objective memory test performance

    Time: 3 months

    Description: Changes on the Multifactorial Memory Questionnaire

    Measure: Subjective memory test performance on the MMQ

    Time: 3 months

    Description: Performance on prose (medical instructions) and spatial (navigation) memory tasks

    Measure: Objective memory test performance

    Time: change from baseline to 3 months

    Description: Changes on the Multifactorial Memory Questionnaire

    Measure: Subjective memory test performance on the MMQ

    Time: change from baseline to 3 months

    Other Outcomes

    Description: Planned analyses to examine patient specific characteristics that affect treatment efficacy and would be vital for clinical translation at the individual patient level. These include: Neuropsychological test scores, brain volumes/cortical thickness, and other possible MRI factors.

    Measure: Planned (tertiary) analyses of patient-specific characteristics that affect treatment outcome

    Time: post treatment (within ~ 96 hours) & 3 months
    2 A Randomized, 24-week Parallel-group Placebo-controlled Multicenter (Phase 2) Study of Anthocyanins in People at Risk for Dementia

    The aim of this project is to study the safety and efficacy of anthocyanins in improving key dementia-related mechanisms and cognitive functioning in older people at risk for dementia. Secondary analyses will include a variety of biological measures, including biochemistry, imaging and cardiovascular measures.

    NCT03419039
    Conditions
    1. Dementia
    2. Inflammation
    3. Mild Cognitive Impairment
    4. Coronary Artery Disease
    Interventions
    1. Dietary Supplement: Anthocyanins
    2. Dietary Supplement: Placebo
    MeSH:Dementia Coronary Artery Disease Inflammation Cognitive Dysfunction
    HPO:Cognitive impairment Coronary artery atherosclerosis Dementia Mental deterioration

    Primary Outcomes

    Description: A composite measure from the CogTrack battery

    Measure: Quality of episodic memory.

    Time: Baseline to 24 weeks

    Secondary Outcomes

    Description: CogTrack evaluates attentional intensity index, sustained intensity index, cognitive reaction time, attentional fluctuation index, quality of working memory, quality of episodic memory and speed of memory retrieval.

    Measure: Secondary endpoints from CogTrack

    Time: Baseline to 24 weeks

    Description: Lipid profile, fatty acids, cytokines ( among others: IL-1, IL-2, IL-6, TNF-a), plasma antoxidant status and vitamins (lipid peroxidation markers, vitamins E, C, A, total plasma antioxidant capacity, glutathion)., carinthine, blood glucose, HbA1c, anthocyanins and metabolites, mapping of a-beta degradation products.

    Measure: Blood outcome analysis

    Time: Baseline to 24 weeks

    Description: Flow-mediated dilation (FMD), Cardiac-ankle vascular index (CAVI), photoplethysmogram (PPG).

    Measure: Cardiovascular parameters

    Time: Baseline to 24 weeks

    Description: Microbiota

    Measure: Fecal analysis

    Time: Baseline to 24 weeks

    Description: kyrinin

    Measure: Urine analysis

    Time: Baseline to 24 weeks

    Description: anthocyanin metabolites

    Measure: CSF measurements

    Time: Baseline to 24 weeks

    Description: Diagnosing and follow-up of cerebrovascular disease

    Measure: MR-imaging/CT

    Time: Baseline to 24 weeks
    3 Cognitive Training in a Multi-task Daily Life Task: a Feasibility Study in Healthy Older Adults

    This study evaluated the feasibility of a web-based computerized cognitive training protocol to healthy older adults. The training protocol will occur in two phases. In the first phase, participants will be randomly allocated in one type of training, and in the second phase all participants will receive the same training.

    NCT04195230
    Conditions
    1. Age-related Cognitive Decline
    Interventions
    1. Behavioral: Table Setting Training
    2. Behavioral: Cooking Training
    3. Behavioral: Multi-tasking Training
    MeSH:Cognitive Dysfunction
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: Change in cooking time (milliseconds) in each food type. In the computerized task, participants are asked to cook different food types. Scores reflect the average absolute values of the difference between the required and actual cooking time of each item. Lowers scores (closest to zero) represent a better outcome.

    Measure: Change in Cooking Time Discrepancy Scores

    Time: During intervention: baseline, two weeks, and one month

    Description: Change in cooking time (milliseconds) between food items. In the computerized task, participants are asked to cook different food types. Scores reflect is the difference between the first and last food item stopped cooking. Lowers scores (closest to zero) represent a better outcome.

    Measure: Change in Range of Stop Times Score

    Time: During intervention: baseline, two weeks, and one month

    Description: Change in the total number of tables set. In the computerized task, participants are asked to set tables for four guests, when finished, one point is given. Higher scores represent a better outcome.

    Measure: Change in the Number of Tables Set Score

    Time: During intervention: baseline, two weeks, and one month

    Secondary Outcomes

    Description: The participants are asked to identify targets and ignore distracting visual information under different conditions. Scores are automatically generated by the software based on the accuracy and reaction time of performance. Higher scores reflect better cognitive ability.

    Measure: Transfer to Speed Processing Task (Change)

    Time: Baseline, two weeks (during the intervention), within one week after the intervention

    Description: Participants are presented with a computer screen of 9 boxes. The boxes light up in a pre-fixed sequence and participants are asked to click on the boxes in the same order they were lit. The sequence length starts at level = 2 boxes and can increase to up to level 9. One point is giving for each correct response. Higher values represent better performance (min 0; max of 16 points).

    Measure: Transfer to Visuospatial Working Memory Task (Change)

    Time: Baseline, two weeks (during the intervention), within one week after the intervention

    Description: Participants are asked to read words and identify letter under different conditions. Scores are based on performance time (seconds) and number of errors.

    Measure: Transfer to Inhibitory Control Task (Change)

    Time: Baseline, two weeks (during the intervention), within one week after the intervention

    Description: Participants listen to series of letters and digits, which they need to organize under specific conditions. One point is giving for each correct response (mix 0; max 30 points).

    Measure: Transfer to Verbal Working Memory Task (Change)

    Time: Baseline, two weeks (during the intervention), within one week after the intervention

    Description: It consists in a test that target three attentional networks involving identifying targets. Lower score represent faster performance.

    Measure: Transfer to Complex Attention Task (Change)

    Time: Baseline, two weeks (during the intervention), within one week after the intervention

    Description: It consist in letters and numbers operations. Accuracy on the alphabetic portion of the Alpha-span task.

    Measure: Transfer to Complex Working Memory Task: the Alpha-span task (Change)

    Time: Baseline, two weeks (during the intervention), within one week after the intervention

    Description: Average z-score computed with outcomes 4 to 9.

    Measure: Transfer to Executive Control Composite Score (Change)

    Time: Baseline, two weeks (during the intervention), within one week after the intervention

    Description: Questionnaire listing cognitive failures in everyday life (self-report measure). Higher scores reflect more cognitive failures or difficulties.

    Measure: Transfer to self-report cognitive failure questionnaire (Change)

    Time: Baseline, two weeks (during the intervention), within one week after the intervention
    4 Improving Aging in Place for Older Adults in Subsidized Housing

    This pilot study will evaluate the feasibility and preliminary effectiveness of an adapted version of the Function Focused Care intervention, delivered by telephone, for improving aging in place for older adults living in subsidized housing. The study will include participants with and without mild cognitive impairment or mild dementia and will examine whether the study outcomes differ by cognitive status. Findings from this study will provide new information about how to optimize function and physical activity among older adults with and without cognitive impairment living in subsidized housing.

    NCT04212442
    Conditions
    1. Physical Disability
    2. Cognitive Impairment
    3. Physical Activity
    Interventions
    1. Behavioral: Independent Living Program for Affordable Housing.
    MeSH:Cognitive Dysfunction
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: Self-reported ability to perform 8 ADLs and 7 IADLs (Range, 0-30; higher scores indicate more functional impairment)

    Measure: Change in Precipitating Events Project (PEP) Functional Status Scale from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Objective measure of lower extremity functioning in older adults (Range, 0-12; higher scores indicate worse lower extremity functioning) The measure will be collected only if in-person contact is possible during the COVID-19 outbreak.

    Measure: Change in Short Physical Performance Battery score from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Measured using Fitbit

    Measure: Change in average step counts from baseline to 2 months for immediate intervention sites; change from 2 to 4 months for waitlist control sites

    Time: Measured continuously from 0-4 months

    Description: Measured using Fitbit (minutes spent in each of 4 levels of activity: sedentary; lightly active; fairly active; very active)

    Measure: Change in time spent in differing levels of activity from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites

    Time: 0-4 months

    Description: Self-reported physical activity (Range, 0-793; higher scores indicate greater physical activity)

    Measure: Change in Physical Activity Scale for the Elderly (PASE) score from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites

    Time: Baseline, 2 months, 4 months for wait-list control

    Secondary Outcomes

    Description: Self-reported measure (Range, 13-52; higher scores indicate better quality of life)

    Measure: Change in Quality of Life in Alzheimer's Disease (QOL-AD) scale from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Self-reported measure of depressive symptoms (Range, 0-27; higher scores indicate worse depressive symptoms)

    Measure: Change in Patient Health Questionnaire (PHQ-9) score from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: 14-item self-reported scale (Range, 14-98; higher scores indicate higher levels of resilience)

    Measure: Change in Resilience Scale (RS-14) score from baseline to 2 months for immediate intervention sites; change from 2 months to 4 months for waitlist control sites

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Self-reported hospitalization

    Measure: Percentage of participants with a hospitalization during the study period (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites)

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Self-reported number of hospitalizations

    Measure: Number of hospitalizations during the study period (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites)

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Self-reported emergency department visit

    Measure: Percentage of participants with an emergency department visit during the study period (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites)

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Self-reported number of emergency department visits

    Measure: Number of emergency department visits during the study period (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites)

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Self-reported or emergency contact-reported move to a higher level of care, defined as a move to assisted living, board and care, or nursing home

    Measure: Percentage of participants with a move to a higher level of care (baseline to 2 months for immediate intervention sites; 2 months to 4 months for waitlist control sites)

    Time: Baseline, 2 months, 4 months for wait-list control

    Description: Assessed using participant responses to invitation to participate in the study (enrolled vs. refused)

    Measure: Feasibility of study recruitment, measured as percentage of eligible participants recruited

    Time: 0-4 months

    Description: Assessed as percentage of participants who remain enrolled in the study

    Measure: Feasibility of study retention, measured as percentage of participants retained over study follow-up

    Time: 0-4 months

    Description: Fidelity checklist including each component, with fidelity measured as the percentage of total study protocol tasks completed (Range, 0-100%; higher percentage indicates higher fidelity)

    Measure: Percentage fidelity to treatment protocol, measured using fidelity checklist

    Time: 0-4 months

    Description: Assessed by psychologist (4 global scores, scored on a 5-point Likert scale from 1 (low) to 5 (high))

    Measure: Fidelity to motivational interviewing, measured using the Motivational Interviewing Treatment Integrity Scale (MITI 4)

    Time: 0-4 months

    Description: Self-reported acceptability of the intervention (5-point Likert scale ranging from very unacceptable (1) to very acceptable (5); higher numbers indicate higher acceptability)

    Measure: Acceptability assessed using a survey question

    Time: 0-4 months

    Description: Self-reported acceptability of the intervention assessed using open-ended questions (e.g., "How did the program fit into your life?"; no pre-specified range as responses are qualitative; more positive responses indicate higher acceptability)

    Measure: Acceptability assessed using qualitative interviews

    Time: 0-4 months
    5 Yoga, Aerobic and Stretching Exercise Effects on Neurocognitive Performance: A Randomized Controlled Trial

    The investigators propose to conduct a 6-month 3-arm randomized controlled exercise trial among older adults to compare the efficacy of yoga with aerobic exercise and stretching-toning exercises on cognitive function, brain structure and function, cardiorespiratory fitness, functional fitness, and inflammatory and molecular markers. Using a single-blind, three arm randomized control trial, 168 older adults ages 55-79 will be assigned to either: a Hatha yoga group, an aerobic exercise group or an active stretching and toning control group. The groups will engage in hour-long group exercise sessions 3x/week. A comprehensive neurocognitive test battery, brain imaging, cardiovascular fitness test, and a blood draw will take place at baseline; end of the 6-month intervention, and at 12-month follow-up. The proposed work will examine the relationship between yoga training and improved cognitive functioning as well as identify neurobiological correlates as potential mechanisms of action through which yoga training exerts its effect on cognitive function. COVID-19 Precautions: Due to COVID-19, all exercise sessions will be conducted live via Zoom video-conferencing such that 1/3rd of the participants in each group will exercise in person with the research staff at UIUC campus once a week while the remaining 2/3rd will tune in via Zoom

    NCT04323163
    Conditions
    1. Aging
    2. Cognitive Decline
    Interventions
    1. Behavioral: Physical Activity
    MeSH:Cognitive Dysfunction
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: A comprehensive neuropsychological battery (part of the NIH toolbox) will be used that assesses different domains of cognitive function, including working memory, attention and executive function.

    Measure: Change in cognitive function

    Time: Baseline, 6 months, 12 months

    Secondary Outcomes

    Description: MRI will be used to measure brain volume.

    Measure: Change in brain structure

    Time: Baseline, 6 months, 12 months

    Description: Functional MRI will be used to measure changes in brain activity during resting state.

    Measure: Change in brain function

    Time: Baseline, 6 months, 12 months

    Other Outcomes

    Description: Brain-derived neurotrophic factor (BDNF) will be assessed through a blood serum analysis at each timepoint.

    Measure: Changes in physiological biomarkers

    Time: Baseline, 6 months, 12 months

    Description: The mediating role of cardiorespiratory fitness will be assessed by using a treadmill based graded exercise test designed to measure peak VO2 capacity

    Measure: Changes in cardiovascular fitness

    Time: Baseline, 6 months, 12 months
    6 COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms

    The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms

    NCT04377425
    Conditions
    1. Neurological Diseases or Conditions
    2. Stroke, Acute
    3. Seizure Disorder
    Interventions
    1. Diagnostic Test: COVID-19 swap test PCR
    MeSH:Stroke Seizures Nervous System Diseases Epilepsy Cognition Disorders Cognitive Dysfunction
    HPO:Bilateral tonic-clonic seizure Cognitive impairment Focal sensory seizure Focal-onset seizure Generalized-onset seizure Mental deterioration Seizure Stroke

    Primary Outcomes

    Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)

    Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms

    Time: 6 months

    Secondary Outcomes

    Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients

    Measure: Three months cognitive function of COVID-19 positive patients

    Time: 3 months

    Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)

    Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients

    Time: 6 months

    Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.

    Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients

    Time: 6 months

    Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients

    Measure: Anosmia in COVID-19 positive patients

    Time: 6 months

    Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls

    Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection

    Time: 24 months

    Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis

    Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients

    Time: 24 months
    7 Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia

    Coronavirus disease 2019 has forced worldwide the implementation of unprecedented restrictions to control its rapid spread and mitigate its impact. The Spanish government has enforced social distancing, quarantine and home confinement. This restriction of daily life activities and separation from loved ones may lead to social isolation and loneliness with health-related consequences in community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers. Additionally, an inadequate access to healthcare and social support services may aggravate chronic conditions. Technology home-based interventions emerge for combating social isolation and loneliness preventing the risk of viral exposure. The aim of this multicentre cohort study is to explore, analyze and determine the impact of social isolation on: 1) cognition, quality of life, mood, technophilia and perceived stress of community-dwelling older adults with mild cognitive impairment or mild dementia, and on caregiver burden; 2) health and social care services access and utilization, and 3) cognitive, social and entertainment use of ICTs. This study will be conducted in two Spanish regions Andalucía (Málaga) and Cataluña (Tarrasa). In total 414 dyads, consisting of a person with mild cognitive impairment or mild dementia (PMCI/MD) and their informal caregiver will be contacted by telephone. Potential respondents will be participants of the SMART 4 MD (N=2921), TV-AssistDem (N=100) and INFINITy (N=23) clinical trials. The change in means in the variables will be analyzed comparing baseline results in the previous studies with those during and after confinement using the ANOVA test of repeated measures or the non-parametric Friedman test if appropriate. The performance of a multivariate analysis of variance (ANCOVA) to introduce possible covariates will also be contemplated. A 95% confidence level will be used.

    NCT04385797
    Conditions
    1. Mild Cognitive Impairment
    2. Dementia
    Interventions
    1. Other: Telephone interview
    MeSH:Dementia Cognitive Dysfunction
    HPO:Cognitive impairment Dementia Mental deterioration

    Primary Outcomes

    Description: The Mini-Mental State Examination (MMSE) (23) will be used to assess the cognitive function of the PMCI/MD. The most common cutoff scores for cognitive impairment and dementia are ranging 23 to 27 over 30. As telephone call interviewing will be the safest means to communicate with the PMCI/MD during and after the COVID-19 pandemic the 22 items telephone version of the MMSE will be used (24). All points of the MMSE can be covered in the telephone version except the last section assessing language and motor skills. In the phone version, we will ask the subject to repeat a phrase and name one item (For example: "Tell me, what is the name of the object you are using to talk to me?"). However, a second item will be not be named, nor will be the person be asked to follow a three-stage command, read and obey a sentence, write a sentence, or copy an intersecting pentagon as in the original version.

    Measure: Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Secondary Outcomes

    Description: The Quality of Life-Alzheimer's Disease Scale (QoL-AD) (19-22) is an instrument specifically designed to measure QoL in PMCI/MD from the perspective of both the patient and the informal caregiver. It is a 13-item measure, which includes assessments of the person´s relationships with friends and family, financial situation, physical condition, mood, memory, and an overall assessment of life quality. Response are 4-point multiple choice options (1 = poor, 2= fair, 3= good, 4 = excellent). Scale scores range from 13 to 52, with higher scores indicating greater quality of life. When cognitive function may be compromised, informal caregivers will complete the QoL-AD, on behalf of the PMCI/MD.

    Measure: Change on quality of life in Alzheimer´s Disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The European Quality of Life 5 Dimensions 3 Levels (EuroQoL-5D-3L) is a standardized generic instrument consisting of a descriptive system and a visual analogue scale (VAS). The descriptive system comprises 5 dimensions covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, moderate problems and extreme problems. A 1-digit number expresses the level selected for that dimension. The digits can be combined into a 5-digit number that describes the patient's health state. The VAS records the patient's self-rated health on a vertical scale, where the endpoints are 100 = 'The best health you can imagine' and 0 = 'The worst health you can imagine'. EuroQoL-5D-3L has been shown to correlate well with QoL-AD, indicating that using both measures side-by-side is compatible.

    Measure: Change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Short Form of the Geriatric Depression Scale (GDS) (25) will be used to assess mood. Of the 15 items, 10 indicate depression when answered positively, while the rest (1, 5, 7, 11, 13) when answered negatively. Scores of 0-4 are considered normal, 5-8 indicate mild depression, 9-11 moderate depression, and 12-15 severe depression.

    Measure: Change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Instrument for Measuring Older People's Attitudes Toward Technology (TechPH) measures older people's attitudes and enthusiasm for health technology (26). This instrument refers to technophilia as a person's enthusiasm for and positive feelings toward their technology use and absence of the fears and doubts some older people could have about their ability to manage using new technology. The six items of the instrument measure two factors of technophilia: 3 items concerning techEnthusiasm and 3 items techAnxiety. Response are constructed with a five-point Likert scale questionnaire, ranging from 1 (fully disagree) to 5 (fully agree).

    Measure: Change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Perceived Stress Scale (PSS) measures the degree to which situations in one's life are appraised as stressful. The scale has 10 questions regarding feelings and thoughts during the last month and are rated according to frecuency 0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items

    Measure: Change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Zarit Burden Interview (ZBI-12) is a 12-item scale with each answer chosen from a 5-point Likert scale (Nearly always=4, Quite frequently=3, Sometimes=2, Rarely=1, Never=0). It is a shortened version of the original scale, was developed specifically for informal caregivers of PMCI/MD and covers issues such as caregiver stress and the degree to which caring is affecting their health and social life. Total score range 0 to 48 (0-10= no to mild burden, 10-20= mild to moderate burden >20= high burden).

    Measure: Change on caregiver burden prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Client Service Receipt Inventory (CSRI) (32,33) scale will be used to evaluate the service utilization. This scale is an internationally used method for gathering data on service utilization and other domains relevant for economic analysis of mental health care. It has five sections: background client information, accommodation and living situation, employment history, earnings and benefits, a record of services usually used and information about informal caregiver support. The sections assessed will be consultations, admissions and visits, grouped into subsections according to hospital, specialist, primary or home care. Treatment related to hospital admissions or illness exacerbation will also be assessed. It´s adaptability ensures it is compatible with the research aims, context, participants' likely circumstances, and the quantity and precision of information required.

    Measure: Change on healthcare and social support services access prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: Use of ICTs (SmartPhone, Tablet, Computer, Smart-TV, or other) to contact healthcare and social support services, to stimulate cognition, to facilitate social connectedness (telephone call, video call, texting...), to access COVID-19 information and to enable entertainment.

    Measure: Change from health, cognitive, social, informative and entertainment related uses of ICT during and after confinement.

    Time: Through study completion, an average of 6 months
    8 Care at 360º: A Long-term Individual Cognitive Stimulation Program for Older Adults With Neurocognitive Disorders, Non-Institutionalized and Socially Vulnerable

    The aim of the intervention proposed in the present study is to assess the effect of a cognitive stimulation (CS) intervention program in an individual and long-term format, for non-institutionalized elderly people with neurocognitive disorders and in a situation of social vulnerability. Specifically, to test the effectiveness of CS on the global cognitive state, on mood state, on quality of life and on functional state. The program will be composed by 50 sessions, including three of assessment sessions (pre, intra and post-intervention). Each session will have a duration of 45 minutes with a weekly frequency. Control group participants will maintain their treatment as usual.

    NCT04417751
    Conditions
    1. Neurocognitive Disorders
    2. Dementia
    3. Cognitive Impairment
    4. Cognitive Decline
    5. Cognitive Dysfunction
    6. Social Behavior
    Interventions
    1. Behavioral: Cognitive Stimulation
    MeSH:Dementia Cognitive Dysfunction Neurocognitive Disorders
    HPO:Cognitive impairment Dementia Mental deterioration

    Primary Outcomes

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

    Measure: Cognitive state evaluated through Mini-Mental State Examination

    Time: Pre-intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

    Measure: Change in cognitive state evaluated through Mini-Mental State Examination

    Time: 6 months after the beginning of the intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

    Measure: Change in cognitive state evaluated through Mini-Mental State Examination

    Time: 12 months after the beginning of the intervention

    Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

    Measure: Cognitive performance evaluated through Montreal Cognitive Assessment

    Time: Pre-intervention

    Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

    Measure: Change in cognitive performance evaluated through Montreal Cognitive Assessment

    Time: 6 months after the beginning of the intervention

    Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

    Measure: Change in cognitive performance evaluated through Montreal Cognitive Assessment

    Time: 12 months after the beginning of the intervention

    Secondary Outcomes

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

    Measure: Depressive symptoms evaluated through Geriatric Depression Scale -15

    Time: Pre intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

    Measure: Change in depressive symptoms evaluated through Geriatric Depression Scale -15

    Time: 6 months after the beginning of the intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

    Measure: Change in depressive symptoms evaluated through Geriatric Depression Scale -15

    Time: 12 months after the beginning of the intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

    Measure: Quality of life evaluated through Quality of Life - Alzheimer's Disease: score

    Time: Pre-intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

    Measure: Change in quality of life evaluated through Quality of Life - Alzheimer's Disease: score

    Time: 6 months after the beginning of the intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

    Measure: Change in quality of life evaluated through Quality of Life - Alzheimer's Disease: score

    Time: 12 months after the beginning of the intervention

    Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

    Measure: Functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

    Time: Pre-intervention

    Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

    Measure: Change in functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

    Time: 6 months after the beginning of the intervention

    Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

    Measure: Change in functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

    Time: 12 months after the beginning of the intervention

    Other Outcomes

    Description: Sociodemographic data will be collected using a sociodemographic questionnaire, designed specifically for this study, regarding information about age, gender, literacy, health conditions, among others.

    Measure: Sociodemographic data collected through a sociodemographic questionnaire

    Time: Pre-intervention

    Description: Adherence to the intervention and dropouts will be assessed using a session form, designed specifically for this study, completed by the technician after each session, regarding the attendance and mood/behavior of the participants throughout the intervention sessions.

    Measure: Adherence to the intervention and dropouts evaluated through a session form

    Time: [Pre, intra (6 months) and post intervention (12 months)]
    9 A Randomized Control Trial Examining the Treatment Efficacy of a Novel Approach to Cognitive Remediation in Individuals With Post-Traumatic Stress Disorder

    This study will evaluate the effect of a manualized treatment (Goal Management Training, or GMT) on the cognitive impairments associated with PTSD (Post-Traumatic Stress Disorder) in certain populations. Participants will be randomized to either GMT group treatment, or a wait-list condition.

    NCT04457271
    Conditions
    1. PTSD
    2. Post-traumatic Stress Disorder
    3. Cognitive Impairment
    4. Cognitive Dysfunction
    5. Cognitive Deficit
    Interventions
    1. Behavioral: Goal Management Training (GMT)
    MeSH:Cognitive Dysfunction Stress Disorders, Traumatic Stress Disorders, Post-Traumatic Cognition Disorders
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.

    Measure: Change in Sustained Attention to Response Task (SART) scores from baseline to post-treatment assessment

    Time: 9 weeks

    Description: A computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target presented amidst a background of frequent non-targets. This task assesses inattentiveness, impulsivity, sustained attention, and vigilance.

    Measure: Change in Sustained Attention to Response Task (SART) scores from post-treatment to 3-month follow-up assessment

    Time: 12 weeks

    Description: Assesses the participant's ability to act with forethought, and sequence behaviour in an orderly fashion to reach specific goals (i.e., executive functioning). Similar to the Tower of London test.

    Measure: Change in score on Spatial Planning task (part of Cambridge Brain Science's online battery) from baseline to post-treatment assessment.

    Time: 9 weeks

    Description: Assesses the participant's ability to act with forethought, and sequence behaviour in an orderly fashion to reach specific goals (i.e., executive functioning). Similar to the Tower of London test.

    Measure: Change in score on Spatial Planning task (part of Cambridge Brain Science's online battery) from post-treatment to 3-month follow-up assessment.

    Time: 12 weeks

    Description: A 36-item self-report measure that assesses difficulties with emotion regulation across six domains. A total score is derived by summing all the items - ranging from 36 to 180. Higher scores indicate greater dysfunction in emotion regulation.

    Measure: Change in Difficulties in Emotion Regulation Scale (DERS) score from baseline to post-treatment assessment

    Time: 9 weeks

    Description: A 36-item self-report measure that assesses difficulties with emotion regulation across six domains. A total score is derived by summing all the items - ranging from 36 to 180. Higher scores indicate greater dysfunction in emotion regulation.

    Measure: Change in Difficulties in Emotion Regulation Scale (DERS) score from post-treatment to 3-month follow-up assessment

    Time: 12 weeks

    Description: Gold standard, clinician administered PTSD assessment tool; min. score=0, max=80, with higher scores representing greater PTSD symptoms

    Measure: Change in Clinician Administered PTSD Scale (CAPS) score from baseline to post-treatment assessment

    Time: 9 weeks

    Description: Gold standard, clinician administered PTSD assessment tool; min. score=0, max=80, with higher scores representing greater PTSD symptoms

    Measure: Change in Clinician Administered PTSD Scale (CAPS) score from post-treatment to 3-month follow-up assessment

    Time: 12 weeks
    10 Sedentary Behaviour and Cognitive Function in Community Dwelling Older People: A Feasibility Study

    Introduction Sedentary behaviour refers to activities of low energy expenditure in lying and sitting positions. Examples include driving, watching television, playing cards, puzzles and working on a computer. Studies suggest that between 60% of older people world-wide reported sitting for more than four hours per day. Sedentary behaviour increases as older people become older, have problems with cognition and when they are very ill. Excessive participating in sedentary behaviours is associated with an increased risk of heart problem, cancer death and diabetes. However, we do not know for certain whether or not participating in sedentary behaviour could cause poorer cognition. What does the study hope to achieve? This feasibility study will test whether the main study, which is planned for later, is workable with regards to the following: - Will reducing sedentary behaviour using our online health coaching intervention (WALC-R) be acceptable to research participants and caregivers? - How many participants can be successfully recruited to the future trial? - What is the rate of adverse event associated with proposed study intervention? Method: This is a 13-week randomised feasibility study. We will randomly assign study participants to either the health coaching intervention (WALC-R) or receiving health guidelines on recommended physical activity. We aim to recruit 40 participants aged 50 and over who have been diagnosed with Mild Cognitive Impairment. The future main study will be larger and test whether: • 'WALC-R', an online intervention designed to reduce participation in sedentary behaviour can improve cognitive function in older people with Mild Cognitive Impairment compared with providing an information sheet about physical activity.

    NCT04464538
    Conditions
    1. Mild Cognitive Impairment
    Interventions
    1. Behavioral: WALC-R
    2. Other: Information leaflet
    MeSH:Cognitive Dysfunction
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: Acceptability of study intervention will be qualitatively assessed at the end of week 13 via semi-structured interviews with study participants.

    Measure: Acceptability of intervention assessed by semi-structured interviews

    Time: Week 13

    Description: Proportion of target recruit sample achieved throughout study duration.

    Measure: Recruitment rate

    Time: Week 13

    Description: Proportion of participants recruited into the study who completed the intervention.

    Measure: Completeness of intervention

    Time: Week 13

    Description: Proportion of people recruited into the study who sustained adverse events.

    Measure: Adverse event rate

    Time: Week 13

    Secondary Outcomes

    Description: Sedentary behaviour and physical activity time per day will be recorded using ActivPAL inclinometer.All participants will be required to wear the ActivPAL continuously for at least 7 days at baseline that will measure habitual sedentary behaviour and walking activity each day (Edwardson et al., 2017). The inclinometer will record how many minutes per day each participant is sedentary and engages in light, moderate and vigorous physical activities. A recording is made of each 60-second period (called an 'epoch'), and this is classified as being sedentary or light, moderate or vigorous physical activity. The researcher will collect data on the total minutes of sedentary behaviour per day, number of disruptions in sedentary behaviour and total time spent in physical activity (minutes per day in light, moderate and vigorous activity).

    Measure: Device measured sedentary behaviour

    Time: Week 1 and 13

    Description: Participants will complete a survey questionnaire about weekly time spent participating in selected sedentary behaviours such as watching television and sitting (Rosenberg et al., 2010). The options for respondents include 'None', <=15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6+ hours.

    Measure: Self reported sedentary behaviour assessed using the Sedentary Behaviour Questionnaire

    Time: Week 1 and 13

    Description: The researcher will test participant's verbal fluency (cognitive function) using the Controlled and Oral Word Association Test. The scores represent the number of correct words provided in 60 seconds. Higher scores represent better verbal fluency ability and vice versa.

    Measure: Verbal fluency assessed using the Controlled and Oral Word Association Test (COWAT)

    Time: Week 1 and 13

    Description: The participants will self- rate their health using five dimensions provided (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and five response levels: no problems, slight, moderate, severe, unable to/extreme problems. The EQ- Visual Analogue Scale(VAS) records the respondent's overall current health (0-100). Higher VAS scores represent best perceived health and vice versa.

    Measure: Perceived quality of life using the EuroQol five-dimension questionnaire (EQ-5D)

    Time: Week 1 and 13

    Description: This will be evaluated using the National Adult Reading Test. Participants will be asked to read form a list of 50 words and they will be scored based on whether or not they pronounce each word correctly.

    Measure: Pre-morbid intelligence

    Time: Week 1 and 13
    11 Impact of Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults With and Without Cognitive Impairment

    The current study will examine the impact of frequent social interaction through communication technologies during COVID-19 pandemic in the cognitive status of socially-isolated older adults with and without cognitive impairment. Patients will take place in an experimental crossover study, participants will complete one month of an intervention and one month of as passive control. The goal of this study is to determine: A.) if frequent social interaction through ICT during COVID-19 pandemic will have a significant positive impact in cognitive performance on testing, and B.) how social isolation and cognitive status influence misconceptions around the current pandemic.

    NCT04480112
    Conditions
    1. Memory Disorders
    2. Alzheimer Disease
    3. Mild Cognitive Impairment
    Interventions
    1. Behavioral: Technology based social interactions
    2. Other: No research related technology based social interactions
    MeSH:Alzheimer Disease Memory Disorders Cognitive Dysfunction
    HPO:Alzheimer disease Cognitive impairment Memory impairment Mental deterioration

    Primary Outcomes

    Description: The Oral Trail Making Test B (TMT-B) will be used to assess memory performance. It is a neuropsychological measure that provides an assessment of sequential set-shifting. Participants are asked to count from 1 to 25 switching between number and letter, eg 1-A-2-B-3-C, until stopped.

    Measure: Change in memory performance

    Time: Baseline,1 month

    Description: Repeatable Battery for the Assessment of Neuropsychological Status (R-BANS) will be administered to assess cognitive decline or improvement. The 12 items on the RBANS assess five cognitive domains: immediate memory, visuospatial/constructional abilities, language, attention, and delayed memory. Scores can range from 0-160 and are interpreted as: 130 and above- very superior; 120-129 - superior; 110-119- high average; 90-109- average; 80-89- low average; 70-79- borderline; 60 and below extremely low.

    Measure: Change in cognition

    Time: Baseline, 1 month

    Description: Phonemic fluency will be assessed by asking participants to produce orally as many words as possible beginning with a specific letter or for a specific category (eg animals, fruits, etc). The test consists of three trials, of 1 min each. The higher the number of words provided, the greater the verbal fluency.

    Measure: Change in phonemic fluency

    Time: Baseline, 1 month

    Secondary Outcomes

    Description: The 6-item version of the Lubben Social Network scale (LSNS-6) will be used to assess social isolation. For each of the 6 questions the participant rates from 0 to 5 their perceived social engagement where 0=less social engagement and 5= more social engagement. The summed total score ranges between 0 and 30. Lower total scores indicate more social isolation.

    Measure: Social isolation

    Time: 1 month

    Description: Loneliness will be assessed using the UCLA loneliness scale. Participants rate each item as either O ("I often feel this way"= 3),S ("I sometimes feel this way"=2), R ("I rarely feel this way"=1), N ("I never feel this way"=0). A total score is computed by adding up the response to each question and can range from 0 to 60. The average loneliness score on the measure is 20. A score of 25 or higher reflects a high level of loneliness. A score of 30 or higher reflects a very high level of loneliness.

    Measure: Loneliness

    Time: 1 month

    Description: The Geriatric Depression Scale (GDS) will be used to assess depression. It consists of 15 questions- 10 indicate the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

    Measure: Depressive symptoms

    Time: 1 month

    Description: An investigator developed questionnaire based on survey results published by Geldsetzer P in Annals of Internal Medicine, 3-2020 will be used to assess Covid-19 misinformation.

    Measure: Misinformation about Covid-19

    Time: 1 month
    12 Effects of BCG Immunization on Cerebrospinal Fluid and Blood-Based Biomarkers in Older Adults: A Pilot

    A pilot study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older adults.

    NCT04507126
    Conditions
    1. Mild Cognitive Impairment
    2. Healthy
    Interventions
    1. Biological: Bacillus Calmette-Guerin (BCG)
    MeSH:Cognitive Dysfunction
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: Change in concentration of circulating cytokines in CSF from baseline

    Measure: CSF biomarkers of pharmacodynamic response- cytokines

    Time: Day 84

    Description: Change in Treg number and proportion relative to total CD4+ and CD8+ T cells in CSF from baseline

    Measure: CSF biomarkers of pharmacodynamic response-Treg

    Time: Day 84

    Description: Change in soluble TNF receptor (sTNF-R) concentration in CSF from baseline

    Measure: CSF biomarkers of pharmacodynamic response-TNFR

    Time: Day 84

    Description: Change in concentration of ATN markers of AD pathophysiology (Amyloid-β42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in CSF from baseline.

    Measure: CSF biomarkers of AD pathology-ATN

    Time: Day 84

    Description: Change in BCG on molecular markers of immune response (YKL40, and sTREM2) concentration from from Baseline.

    Measure: CSF biomarkers of immune response.

    Time: Day 84

    Description: Change in concentration of circulating cytokines in blood from baseline.

    Measure: Blood biomarkers of pharmacodynamic response- cytokines

    Time: Day 28

    Description: Change in concentration of Treg number and proportion (relative to total CD4+ and CD8+ T cells) in blood from baseline.

    Measure: Blood biomarkers of pharmacodynamic response-Treg

    Time: Day 28

    Description: Change in concentration of Soluble TNF receptor (sTNF-R) in blood from baseline.

    Measure: Blood biomarkers of pharmacodynamic response-TNFR

    Time: Day 28

    Description: Change in concentration of circulating cytokines in blood from baseline

    Measure: Blood biomarkers of pharmacodynamic response- cytokines

    Time: Day 84

    Description: Change in Treg number and proportion relative to total CD4+ and CD8+ T cells in blood from baseline

    Measure: Blood biomarkers of pharmacodynamic response- Treg

    Time: Day 84

    Description: Change in soluble TNF receptor (sTNF-R) concentration in blood from baseline

    Measure: Blood biomarkers of pharmacodynamic response- TNFR

    Time: Day 84

    Description: Change in concentration of ATN markers of AD pathophysiology (Amyloid-β42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in blood from baseline.

    Measure: Blood biomarkers of AD pathology

    Time: Day 28

    Description: Change in concentration of ATN markers of AD pathophysiology (Amyloid-β42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in blood from baseline.

    Measure: Blood biomarkers of AD pathology

    Time: Day 84

    Secondary Outcomes

    Description: Change from baseline in Clinical Dementia Rating Sum-of-Boxes (CDR-SOB) score. Score range= 0-18 (0=unimpaired, 18=severe dementia)

    Measure: Cognitive Measures (CDR)

    Time: Day 28

    Description: Change from baseline in Clinical Dementia Rating Sum-of-boxes (CDR-SOB) score. Score range= 0-18 (0=unimpaired, 18=severe dementia)

    Measure: Cognitive Measures (CDR)

    Time: Day 84

    Description: Change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score.

    Measure: Cognitive Measures (RBANS)

    Time: Day 28

    Description: Change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score

    Measure: Cognitive Measures (RBANS)

    Time: Day 84
    13 Telehealth Intervention Program for Older Adults (TIP-OA) Struggling With Mental Health/Cognitive Issues

    COVID-19 is having profound effects on older adults' due to social isolation measures which may negatively impact individuals' mental and physical health. Recently, a telephone program, the Telehealth Intervention Program for Older Adults (TIP-OA), was created. In this program, a volunteer is calling older adults (age≥60) every week to have a friendly conversation. The objective of this study is to evaluate the effectiveness of this telephone program (TIP-OA) in reducing stress, improving the mental health of program users, and understand their experiences.

    NCT04523610
    Conditions
    1. Depression, Anxiety
    2. Cognitive Impairment
    3. Stress
    Interventions
    1. Behavioral: Telehealth phone calls
    2. Other: Volunteer of TIP-OA Program
    3. Other: Stakeholder of TIP-OA Program
    MeSH:Cognitive Dysfunction
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: Perceived Stress Scale (PSS) is a 14-item scale used to measure the degree to which life events are experienced and appraised as stressful. It asks respondents about how often they have felt certain ways in the past month, with responses ranging from 0 (never) to 4 (very often).

    Measure: Perceived Stress Scale (PSS)

    Time: Change from Baseline to 4- and 8-weeks (15 minute assessment)

    Description: Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report questionnaire used to diagnose depression and assess symptom severity. The questionnaire asks individuals how often in the last two weeks they have been bothered by problems like "feeling down, depressed, and hopeless" and "poor appetite or overeating." Scores for each question include 0 (not at all), 1 (several days), 2 (more than half of the days), and 3 (nearly every day).

    Measure: Patient Health Questionnaire-9 (PHQ-9)

    Time: Change from Baseline to 4- and 8-weeks (15 minute assessment)

    Description: Generalized Anxiety Disorder-7 (GAD-7) is a 7-item scale that measures symptoms of anxiety present in the previous 2 weeks. Respondents can choose from a score of 0 (not at all sure), 1 (several days), 2 (over half the days), or 3 (nearly every day). Items include "Not being able to stop or control worrying" and "Being so restless that it's hard to sit still".

    Measure: Generalized Anxiety Disorder-7 (GAD-7)

    Time: Change from Baseline to 4- and 8-weeks (15 minute assessment)

    Description: Fear of COVID-19 Scale is an 18-item scale measuring individuals' anxiety, fear and concern surrounding the COVID-19 pandemic. Items include: "Fear that I will be infected" and "Worry if I will be assigned to COVID wards if hospitalized" (34).

    Measure: Fear of COVID-19 Scale

    Time: Change from Baseline to 4- and 8-weeks (15 minute assessment)

    Secondary Outcomes

    Description: What are the roles, contributions, and challenges of volunteers in identifying the needs of program users and volunteers, providing access to services, and creating appropriate responses to identified needs for the success and efficacy of the program?

    Measure: Interviews and Focus Groups with Volunteers

    Time: 8-weeks (2 hours)

    Description: What are the roles, contributions, and challenges of different stakeholders (e.g. community partners, program organizers, and clinicians) in identifying the needs of program users and volunteers, providing access to services, and creating appropriate responses to identified needs for the success and efficacy of the program?

    Measure: Interviews and Focus Groups with Stakeholders

    Time: 8-weeks (2 hours)

    Description: What are the experiences and evaluation of the program users about their engagement with the TIP-OA? Has the program contributed in improving the health of the program users?

    Measure: Interviews with Program Users

    Time: 8-weeks (2 hours)
    14 NeuroCOVID - A Study of Activation and Inhibition of the Immune and Coagulation Systems, the Presence of Biochemical (Blood / CSF) and Structural Brain Changes and Their Association With Long-term Cognitive Dysfunction in Intensive Care-requiring Covid-19 Patients

    Critically ill patients requiring intensive care suffer to a large extent from cognitive deficits involving higher brain functions that primarily affect memory, learning and the ability to concentrate. While the background to this effect is not fully understood, there are growing evidence to support mechanisms related to neuro inflammation and changes in blood flow with concomitant ischemic brain damage. Patients with covid-19 often suffer from severe inflammatory activity with an increased risk of coagulation abnormalities and brain damage. Covid-19 patients requiring intensive care develope more severe impairment of neurological and cognitive function than critically ill intensive care patients who have not covid-19. This project therefore aims to map the link between inflammation, immunology and coagulation systems as well as biochemical and structural changes in the brain with cognitive effects in patients in intensive care for covid-19.

    NCT04578197
    Conditions
    1. Covid19
    MeSH:Cognitive Dysfunction
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Measure: The association between changes in blood biomarkers for inflammation and the presence of neuroradiologically verified brain injury and neurocognitive disorder

    Time: Up to 12 months

    Measure: The association between changes in blood biomarkers for nerve cell damage and the presence of neuroradiologically verified brain injury and neurocognitive disorder

    Time: Up to 12 months

    Measure: The association between changes in blood biomarkers for neurodegeneration and the presence of neuroradiologically verified brain injury and neurocognitive disorder

    Time: Up to 12 months

    Secondary Outcomes

    Measure: The association between changes in coagulation factors and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder

    Time: Up to 12 months

    Measure: The association between changes in coagulation ability (ROTEM analysis - rotational thromboelastometry) and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder

    Time: Up to 12 months

    Measure: The association between changes in inflammatory biomarkers and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder

    Time: Up to 12 month

    Description: Markers of inflammation impact - in relation to cerebrospinal fluid changes .

    Measure: Blood biomarker changes of inflammation impact

    Time: Up to 3 months

    Description: Markers of neurological impact - in relation to cerebrospinal fluid changes .

    Measure: Blood biomarker changes of neurological impact

    Time: Up to 3 months

    Description: Neurological impact in relation to cerebrospinal fluid changes

    Measure: Neuroradiological changes

    Time: Up to 3 months

    Description: in relation to cerebrospinal fluid changes/blood

    Measure: Clinical course - Pulmonary gas exchange

    Time: Up to 3 months

    Description: in relation to cerebrospinal fluid changes/blood

    Measure: Clinical course - Lung function recording

    Time: Up to 3 months

    Description: Patient ICU care data - in relation to cerebrospinal fluid changes

    Measure: Patient characteristics

    Time: Up to 3 months
    15 Long-term Cognitive Impairment in ICU Patients, Admitted for COVID-19 Pneumonia: a Single Centre, Prospective Cohort Study

    Acute Respiratory Distress syndrome (ARDS) is a pulmonary systematic inflammatory response, leading to acute respiratory failure with hypoxia and/or hypercarbia. COVID-19 evokes a viral pneumonia, which may result in ARDS as well. It is not yet clear if COVID-19 disease behaves like the typical ARDS. Corona virus causes primarily deep hypoxia. Hypoxia, on its own, can lead to long term cognitive impairment. However, critical illness also affects long-term neurocognitive functioning. The investigators will be researching the possibility of long-term cognitive impairment in COVID-19 ICU patients, in comparison with reference values of a healthy population as well as the values measured in critically ill patients, admitted not only for respiratory reasons.

    NCT04593069
    Conditions
    1. Covid19
    2. Cognitive Impairment
    Interventions
    1. Behavioral: Neurocognitive assessment
    MeSH:Cognitive Dysfunction
    HPO:Cognitive impairment Mental deterioration

    Primary Outcomes

    Description: the Repeatable Battery for the Assessment of Neuropsychological Statusis (RBANS) is a neuropsychological test that provides information about 5 domains of cognition (1) immediate and (2) delayed memory, (3) attention, (4) visuospatial construction and (5) language) and provides a total score. It is a test that takes about 30 minutes and consists of twelve tests. These are: (1) List Learning, (2) Story Memory, (3) Figure Copy, (4) Line Orientation, (5) Picture Naming, (6) Semantic Fluency, (7) Digit Span, (8) Coding, (9) List Recall, (10) List Recognition, (11) Story Recall and (12) Figure Recall. According to the RBANS manual, the possible values for the RBANS scores at the item, domain, and scale level are 0 to 89, 40 to 154, and 40 to 160

    Measure: Neurocognitive impairment measured by RBANS

    Time: 6 months after admission at the intensive care unit

    Secondary Outcomes

    Description: Trail Making Test (TMT) is a test of executive functioning, visual search speed, scanning, speed of processing and mental flexibility. The total score is the time in seconds spent to complete each part.

    Measure: Neurocognitive impairment measured by TMT

    Time: 6 months after admission at the intensive care unit

    Description: The short IQCODE is a 16 question long questionnaire that assesses cognitive impairment in elderly patients. An informant is required to rate a patient's cognitive changes over a 10 year time period. Each question is scored from 1 (much improved over time) to 5 (much worse).

    Measure: Neurocognitive impairment by the short IQCODE

    Time: 6 months after admission at the intensive care unit

    HPO Nodes


    HP:0001268: Mental deterioration
    Genes 494
    PRDM8 KCNA2 VCP TRNL1 TBP SNCB DNAJC13 PNPLA6 MAPT RBM28 COMT PDE11A SCN8A PSEN2 ERCC8 PRNP ERCC6 GRN TREM2 EEF1A2 FTL HFE SNCA GBA2 ACTL6B TYMP SNCA HTT MAPT TTR CHD2 SYNJ1 TRNE C19ORF12 SYNJ1 NPC1 ABCC8 ATXN2 WFS1 C9ORF72 CSTB WWOX COX3 CYTB MFN2 ZFYVE26 PRKN NDP CHI3L1 ADH1C ACTB LRRK2 AUH TLR3 MAPT DNAJC6 GDAP2 SLC44A1 CHCHD10 TINF2 CREBBP C9ORF72 COX2 SDHA PMPCA CUBN NECAP1 PDGFB NHLRC1 GABRB2 PLA2G6 PINK1 GABRA2 WDR45 NAGLU CHMP2B NOTCH2NLC TOMM40 GALC TRAK1 CSF1R CHMP2B COL18A1 VCP SCN3A JAM2 ARSA TIMM8A HIBCH TREX1 TRNH MATR3 CHMP2B HGSNAT LYST GRN MPO PRNP APP TREM2 CUX2 PPP2R2B CYFIP2 NBN CACNA1B COASY ND1 ADA2 CLN6 CST3 ATP6V1A SQSTM1 CLN6 MECP2 ABCD1 DNAJC5 PDGFRB TREM2 PSAP SLC13A5 HNF4A ATP6V1E1 ATXN2 MYORG GBA SLC20A2 FMR1 COL4A1 HLA-DQB1 SLC13A5 ATXN7 PLP1 SCARB2 PSAP GABRA5 GRN PSEN1 TYROBP PSEN1 ATN1 RNF216 CHMP2B NRAS APOE TRNS2 TRNS1 NOTCH3 HTT XPR1 ROGDI NR4A2 TK2 SURF1 SNCA PSAP CREBBP SPG11 TRNK APP OPA1 MAPT RRM2B TBK1 DGUOK GBA2 ITM2B WFS1 TARDBP ND4 PDE10A POLG APP APOL2 GBA TUBA4A ND5 LRRK2 SLC6A1 SPG21 PANK2 UBAP1 PSEN2 GRIN2D MFSD8 PRKAR1A DNM1 CP COX1 PRNP SORL1 CLN8 UBQLN2 CYP27A1 ND6 RAB27A GALC HEXA PRDX1 MAPT A2M QDPR ATP6 APP MMACHC VCP CERS1 SNORD118 ALDH18A1 HNRNPA2B1 TRNK TBK1 TYROBP GABRG2 SQSTM1 HTRA1 AARS2 SUMF1 ARV1 STXBP1 GALC FA2H DCTN1 HTT SLC1A2 RRM2B TIMM8A CLN8 CLTC ASAH1 ASAH1 CPLX1 SLC2A3 HSD17B10 NDUFAF3 NTRK2 PPT1 TRNF GBE1 KCNB1 MAPT FTL VCP C9ORF72 PLA2G6 NHLRC1 DNM1L HEXB ERCC8 UCHL1 PSEN1 POLG MAPT HCN1 PSEN1 PLAU FBXO7 APOE MAPT CHCHD10 UCP2 MTHFR SNCAIP AARS1 TRNL1 ATP7B COX1 NDUFA6 DISC2 PARK7 PTS CTC1 AP2M1 GLB1 PRNP GIGYF2 PSAP GRN IRF6 C9ORF72 TREX1 APP PDGFRB KCNC1 ATP13A2 SMC1A PINK1 PPP2R2B HMBS PRNP MAPT FA2H PRNP CDK19 GLUD2 PSEN1 TRPM7 SCO2 GBA SYN2 ATP6V0A2 IDUA PSEN1 PANK2 MCOLN1 RNASEH1 SYNGAP1 ROGDI PPP3CA CNTNAP2 DNMT1 KCNJ11 FUS GCH1 SNCA ATP1A2 DAOA SPG11 SYNJ1 TBK1 MAPT SCN1A SNCA SERPINI1 HNRNPA1 SDHD TBC1D24 VPS13C GCDH GBA APP ATP6 CSF1R PDGFRB DRD3 TRNQ TRNQ SYNJ1 DCTN1 SPG21 AP3B2 CACNA1A AP5Z1 TIMMDC1 PRKCG RTN4R TBP PODXL FGF12 TRNF ATP13A2 ADA2 VCP PLEKHG4 CTSD ATXN7 PDGFB C9ORF72 JPH3 EPM2A TTPA GNAS KMT2A CLN5 NPC2 PARS2 DARS2 JPH3 HNF1A ERCC2 DCAF17 HTR2A LRRK2 EPM2A VCP TMEM106B COX3 ALDH18A1 PRNP MATR3 ATP13A2 VPS13C TMEM106B SNCA ND1 VPS35 UBA5 EIF4G1 EP300 PRNP XPA GRN SQSTM1 MTHFR DNMT1 NDUFB8 GABRB3 TRNW PRDM8 TRNS2 TREM2 SDHAF1 CSTB ERCC6 COX2 TWNK GM2A ERCC4 RNF216 GBA ATXN10 DHDDS PRKAR1B KCTD7 GALC PRICKLE1 NDUFS2 DNM1 APP TRNV RBM28 BSCL2 TARDBP ATP1A3 NUS1 KCNA2 MAPT PAH DALRD3 SCN1A YWHAG TREM2 PLA2G6 SQSTM1 MAPK10 GBA MBTPS2 BSCL2 FA2H CNKSR2 SPAST RAB39B VPS13A ATN1 VPS13A CTNS ARSA SZT2 ATXN3 CLN3 MAPT CTSF ATXN2 MAPT APOL4 TRNW CHMP2B TRNC HNRNPA2B1 SGPL1 TBP NOTCH3 DNMT1 ND6 WDR45 ATXN8OS SUMF1 CFAP43 ITM2B FMR1 APTX LMNB1 UBTF ND5 ATP6V1A TUBB4A TREM2 CISD2 RRM2B ARSA HTRA1 ATP13A2 NOTCH2NLC ABCA7 PSEN1 NOS3 DMPK C19ORF12 HEPACAM TMEM106B CHD2 HTRA2 TRNS1 GBA SDHB
    Protein Mutations 3
    K56M V158M V66M

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0001268: Mental deterioration
    Genes 494
    PRDM8 KCNA2 VCP TRNL1 TBP SNCB DNAJC13 PNPLA6 MAPT RBM28 COMT PDE11A SCN8A PSEN2 ERCC8 PRNP ERCC6 GRN TREM2 EEF1A2 FTL HFE SNCA GBA2 ACTL6B TYMP SNCA HTT MAPT TTR CHD2 SYNJ1 TRNE C19ORF12 SYNJ1 NPC1 ABCC8 ATXN2 WFS1 C9ORF72 CSTB WWOX COX3 CYTB MFN2 ZFYVE26 PRKN NDP CHI3L1 ADH1C ACTB LRRK2 AUH TLR3 MAPT DNAJC6 GDAP2 SLC44A1 CHCHD10 TINF2 CREBBP C9ORF72 COX2 SDHA PMPCA CUBN NECAP1 PDGFB NHLRC1 GABRB2 PLA2G6 PINK1 GABRA2 WDR45 NAGLU CHMP2B NOTCH2NLC TOMM40 GALC TRAK1 CSF1R CHMP2B COL18A1 VCP SCN3A JAM2 ARSA TIMM8A HIBCH TREX1 TRNH MATR3 CHMP2B HGSNAT LYST GRN MPO PRNP APP TREM2 CUX2 PPP2R2B CYFIP2 NBN CACNA1B COASY ND1 ADA2 CLN6 CST3 ATP6V1A SQSTM1 CLN6 MECP2 ABCD1 DNAJC5 PDGFRB TREM2 PSAP SLC13A5 HNF4A ATP6V1E1 ATXN2 MYORG GBA SLC20A2 FMR1 COL4A1 HLA-DQB1 SLC13A5 ATXN7 PLP1 SCARB2 PSAP GABRA5 GRN PSEN1 TYROBP PSEN1 ATN1 RNF216 CHMP2B NRAS APOE TRNS2 TRNS1 NOTCH3 HTT XPR1 ROGDI NR4A2 TK2 SURF1 SNCA PSAP CREBBP SPG11 TRNK APP OPA1 MAPT RRM2B TBK1 DGUOK GBA2 ITM2B WFS1 TARDBP ND4 PDE10A POLG APP APOL2 GBA TUBA4A ND5 LRRK2 SLC6A1 SPG21 PANK2 UBAP1 PSEN2 GRIN2D MFSD8 PRKAR1A DNM1 CP COX1 PRNP SORL1 CLN8 UBQLN2 CYP27A1 ND6 RAB27A GALC HEXA PRDX1 MAPT A2M QDPR ATP6 APP MMACHC VCP CERS1 SNORD118 ALDH18A1 HNRNPA2B1 TRNK TBK1 TYROBP GABRG2 SQSTM1 HTRA1 AARS2 SUMF1 ARV1 STXBP1 GALC FA2H DCTN1 HTT SLC1A2 RRM2B TIMM8A CLN8 CLTC ASAH1 ASAH1 CPLX1 SLC2A3 HSD17B10 NDUFAF3 NTRK2 PPT1 TRNF GBE1 KCNB1 MAPT FTL VCP C9ORF72 PLA2G6 NHLRC1 DNM1L HEXB ERCC8 UCHL1 PSEN1 POLG MAPT HCN1 PSEN1 PLAU FBXO7 APOE MAPT CHCHD10 UCP2 MTHFR SNCAIP AARS1 TRNL1 ATP7B COX1 NDUFA6 DISC2 PARK7 PTS CTC1 AP2M1 GLB1 PRNP GIGYF2 PSAP GRN IRF6 C9ORF72 TREX1 APP PDGFRB KCNC1 ATP13A2 SMC1A PINK1 PPP2R2B HMBS PRNP MAPT FA2H PRNP CDK19 GLUD2 PSEN1 TRPM7 SCO2 GBA SYN2 ATP6V0A2 IDUA PSEN1 PANK2 MCOLN1 RNASEH1 SYNGAP1 ROGDI PPP3CA CNTNAP2 DNMT1 KCNJ11 FUS GCH1 SNCA ATP1A2 DAOA SPG11 SYNJ1 TBK1 MAPT SCN1A SNCA SERPINI1 HNRNPA1 SDHD TBC1D24 VPS13C GCDH GBA APP ATP6 CSF1R PDGFRB DRD3 TRNQ TRNQ SYNJ1 DCTN1 SPG21 AP3B2 CACNA1A AP5Z1 TIMMDC1 PRKCG RTN4R TBP PODXL FGF12 TRNF ATP13A2 ADA2 VCP PLEKHG4 CTSD ATXN7 PDGFB C9ORF72 JPH3 EPM2A TTPA GNAS KMT2A CLN5 NPC2 PARS2 DARS2 JPH3 HNF1A ERCC2 DCAF17 HTR2A LRRK2 EPM2A VCP TMEM106B COX3 ALDH18A1 PRNP MATR3 ATP13A2 VPS13C TMEM106B SNCA ND1 VPS35 UBA5 EIF4G1 EP300 PRNP XPA GRN SQSTM1 MTHFR DNMT1 NDUFB8 GABRB3 TRNW PRDM8 TRNS2 TREM2 SDHAF1 CSTB ERCC6 COX2 TWNK GM2A ERCC4 RNF216 GBA ATXN10 DHDDS PRKAR1B KCTD7 GALC PRICKLE1 NDUFS2 DNM1 APP TRNV RBM28 BSCL2 TARDBP ATP1A3 NUS1 KCNA2 MAPT PAH DALRD3 SCN1A YWHAG TREM2 PLA2G6 SQSTM1 MAPK10 GBA MBTPS2 BSCL2 FA2H CNKSR2 SPAST RAB39B VPS13A ATN1 VPS13A CTNS ARSA SZT2 ATXN3 CLN3 MAPT CTSF ATXN2 MAPT APOL4 TRNW CHMP2B TRNC HNRNPA2B1 SGPL1 TBP NOTCH3 DNMT1 ND6 WDR45 ATXN8OS SUMF1 CFAP43 ITM2B FMR1 APTX LMNB1 UBTF ND5 ATP6V1A TUBB4A TREM2 CISD2 RRM2B ARSA HTRA1 ATP13A2 NOTCH2NLC ABCA7 PSEN1 NOS3 DMPK C19ORF12 HEPACAM TMEM106B CHD2 HTRA2 TRNS1 GBA SDHB
    Protein Mutations 3
    K56M V158M V66M

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook